Advanced Search
| Home | Sitemap | Contact us
Review
Table of Contents
Abstract
Full Text
PDF Links PDF Links
JCU 2018 March;26(1) :1-25.
Published online 2018 March 28. doi:https://doi.org/10.4250/jcu.2018.26.1.1
Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography
Hyungseop Kim, MD1, Woo-Baek Chung, MD2, Kyoung Im Cho, MD3, Bong-Joon Kim, MD3, Jeong-Sook Seo, MD4, Seong-Mi Park, MD5, Hak Jin Kim, MD6, Ju-Hee Lee, MD7, Eun Kyoung Kim, MD8, and Ho-Joong Youn, MD2*
1Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea
2Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Division of Cardiology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea
4Division of Cardiology, Department of Internal Medicine, Busan Paik Hospital, Inje University, Busan, Korea
5Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
6Department of Cardiology, Center for Clinical Specialty, National Cancer Center, Goyang, Korea
7Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea
8Division of Cardiology, Department of Medicine, Cardiovascular and Stroke Imaging Center, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Corresponding Author: Ho-Joong Youn ,Tel: +82-2-2258-6029, Fax: +82-2-591-1506, Email: younhj@catholic.ac.kr
ABSTRACT
Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.
Keywords: Cardiovascular toxicity · Cardio-oncology · Anti-cancer treatment · Echocardiography
Volume 26, No 1
e-submission
JCU
KSE-JCU
Korean Society of Journal of Cardiovascular Ultrasound Office
1215 Hyundaihyel, 173 Mapo-daero, Mapo-gu, Seoul, 04130, Korea
TEL : +82-2-3147-0930   FAX:+82-2-3147-0933   E-mail: kse0930@ksecho.org
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright@2011 Korean Society of Journal of Cardiovascular Ultrasound Research. All right reserved.